



## **XTACY Therapeutics Corporate Update Introduces Itself as Pegasus Mercantile Inc.**

**Vancouver: October 28, 2024 – Xtacy Therapeutics Corp. (CSE: XTCY) (Frankfurt: TT5) (OTC: XTCYF) (“the Company)** is pleased to announce that, effective October 31, 2024, it will be changing its corporate name to "Pegasus Mercantile Inc. The Company's stock symbol on the Canadian Securities Exchange will also be changed to "LOAN", and the Company expects its shares will commence trading under the new name and ticker symbol on or about market opening on or about Tuesday, October 31, 2024. A new CUSIP number has been obtained to replace the previous CUSIP number.

No action will be required by existing shareholders with respect to the name change. Certificates representing common shares of the Company will not be affected by the name change and will not need to be exchanged. The Company encourages any shareholder with any questions or concerns to contact the Company or to discuss any of the foregoing with their broker or agent.

The Company's current investment strategy has not changed, it provides our investors with an opportunity to gain exposure to unique investments and income from advisory services. Specifically, the Corporation seeks to provide debt instruments and equity investing in the mid to late stages of a target company's development or in technologies that are developed and validated but may be in the early stage of commercialization. This strategy allows the Corporation to invest in enterprises that are commercially viable and have visibility toward high growth. The Corporation is not bound to commit to any particular sector, thereby allowing for diversification; however, the present focus is generally on cannabis-related, healthcare-related target companies, CBD and psychedelics. This approach may change over time as market conditions change and the capital markets respond. The Corporation evaluates each opportunity on its merit. The Corporation enters investments at a stage where potential exists to maximize strong returns and manages risk by applying the considerable business expertise of its directors, officers and advisors to the investments undertaken. The Company believes this is at or near the early stage of the cycle for these-focused companies and as such, the Corporation is poised to take advantage of significant growth in this sector. We will continue to promote companies focused in cannabis, hemp, and psychedelics.

The new CUSIP and ISIN numbers for the Name and Symbol Change will be 70557Y105 and CA70557Y1051 respectively.

---

**About Pegasus Mercantile Inc. :**

Pegasus is a prospect generator that provides high growth companies with financial, operational, and management assistance in the fast growing market for wellness consumer products. The focus of the Company is on global wellness, psychedelics, mycology, hemp and CBD, healthcare-related target companies and their clinical studies and trials.

**For further information visit websites: [www.xtacytherapeutics.com](http://www.xtacytherapeutics.com)**

Or Contact Meris Kott CEO 561.212.3323 or email to [info@xtacytherapeutics.com](mailto:info@xtacytherapeutics.com)

Further information about the Company is available on [www.SEDARplus.com](http://www.SEDARplus.com) under the Company's profile.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.